Journal of Cellular and Molecular Pharmacology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • J Cell Mol Pharmacol,

Antimetastatic Mechanisms of Bisdioxopiperazine Compound Study, A Gateway to Success

Da-Yong Lu1,2*, Jian Ding1, Rui-Ting Chen1, Bin Xu1, Nagendra Sastry Yarla3 and Ting-Ren Lu2
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China
2Shanghai University, Shanghai, PR China
3GITAM University, AP, India
*Corresponding Author : Da-Yong Lu, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China, Tel: +862166163545, Fax: +862166132177, Email: ludayong@shu.edu.cn

Received Date: Aug 15, 2017 / Accepted Date: Aug 20, 2017 / Published Date: Aug 30, 2017

Abstract

Neoplasm metastasis is the causality of 90% cancer patient’s mortality. Bisdioxopiperazine compounds (Biz compounds) are a series of synthetic agents that are firstly discovered to exhibit antimetastatic efficacy to animal tumor models. In order to completely overcome neoplasm metastasis in clinics, antimetastatic therapeutic study for Biz compounds is of great clinical significance. This editorial highlights these researches from new perspective.

Keywords: Bisdioxopiperazine compounds; Probimane; Razoxane; MST-16; Antimetastatic drugs; Neoplasm metastasis; Drug combinations, Drug development

Citation: Lu DY, Ding J, Chen RT, Xu H, Yarla NS, et al. (2017) Antimetastatic Mechanisms of Bisdioxopiperazine Compound Study, A Gateway to Success. J Cell Mol Pharmacol 1: e101.

Copyright: © 2017 Lu DY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top